Is BPC-157 better than traditional wound treatments
Reuben A, Zhang J, Gittelman R, Chiou SH, Li J, Fujimoto J, Behrens C, Kheradmand F, Chow CW, Bernatchez C, Eterovic AK, Benzeno S, Vignali M, Wu X, Ye Y, Cascone T, Rerbst R, Swisher SG , Kadara H, Moran C, Zhang J, Scheet P, Vaporciyan A, Sepesi B, Gibbons D, Robins H, Hwu P, Heymach J, Sharma P, Allison J, Lee J, Davis M, Wistuba I, Futreal A, Zhang J
True nonresponse is less common than people assume: across major studies of semaglutide and tirzepatide, only about 10% to 15% of patients failed to lose at least 5% of their starting body weight (Yale Medicine)
The external reviewer is an independent medical professional, not an employee of the insurance company